

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Michael Paul Brown, et al.	<b>Examiner:</b>	K. T. Hiriyan
<b>Serial No.:</b>	10/569,157	<b>Art Unit:</b>	1633
<b>Filed:</b>	October 13, 2006	<b>Docket:</b>	19610
<b>For:</b>	POXVIRUS VECTOR ENCODING PROSTATE SPECIFIC ANTIGENS FOR TREATMENT OF PROSTATE CANCER	<b>Dated:</b>	May 15, 2009

**Confirmation No.:** 7808

Commissioner for Patents  
Alexandria, VA 22313-1450

**RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143**

Sir:


In response to the Office Action dated March 26, 2009, setting forth a requirement for restriction, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group I, claims 1-19 and 21, drawn to a genetic vaccine construct comprising an avipoxvirus that expresses a prostate specific polypeptide or a derivative thereof and optionally a sequence of nucleotides encoding an immunostimulatory peptide, and to a hybridization probe. Further, in connection with the requirement for species election, Applicants provisionally elect IL-2.

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website on the date shown below.

Dated: May 15, 2009

  
Xiaochun Zhu